Multidrug resistant bacteria are a major contributor of hospital-acquired infections (4 million cases/year in Europe) and costs of medical care (€ 1.5 billion/year). To contribute to the fight against antibiotic resistant pathogens, we are investigating new drugs based on the inhibition of novel virulence mechanisms for the pathogen Pseudomonas aeruginosa. This innovative therapeutic approach will reduce the resistance development induced by treatments and support the cure of bacterial infections.
- Field: Life sciences
- Laboratory: SV-UPPERSAT
- Project leader: Alix Pham
- Budget: 30’000.00 CHF